ApolloBio's Phase 3 trial of INOVIO's VGX-3100 for cervical dysplasia meets primary endpoint, supporting China regulatory submission.

ApolloBio announced positive topline results from its Phase 3 trial of VGX-3100, INOVIO's DNA immunotherapy for HPV-related cervical dysplasia. The trial met its primary efficacy endpoint and showed a favorable safety profile, supporting ApolloBio's plan to seek regulatory approval in China. VGX-3100 aims to offer a non-surgical treatment option for cervical dysplasia caused by HPV types 16 and 18, potentially reducing the need for surgery and associated fertility risks. INOVIO stands to receive milestone payments and royalties if VGX-3100 is approved and marketed in China.